Virtual consulting · Worldwide
NeuciteConsultingRequest a quote

Formulation development for drugs, cosmetics and hydrogels

Product fading, crystallizing, separating or releasing too fast? We find the chemical cause and design the smallest set of studies that shows whether the fix works. Topical, injectable, cosmetic and hydrogel products.

Formulation problems are usually chemistry problems

Formulation development succeeds when the active, the excipients and the container are understood together. Most failures have a mechanism: oxidation, hydrolysis, pH drift, crystallization, phase separation or polymer degradation. Finding that mechanism is faster than screening dozens of trial batches. We work from first principles and the literature, then design a small set of experiments that test the likely explanations. You get a formulation strategy with reasons, not just a recipe.

Our work spans pharmaceutical formulation development for topical and parenteral products, cosmetic and nutraceutical formulations, and biomaterial systems. Hydrogels are a core focus, including synthetic and natural polymers, physical and chemical crosslinking, in-situ gelling systems and controlled release. We also work with emulsions, nanoemulsions, liposomes and cyclodextrin complexes for poorly soluble actives.

Every recommendation comes with a way to check it. We define the analytical methods, stress conditions and acceptance criteria that show whether the formulation holds. For drug products, the stability study design follows ICH Q1A principles, with photostability testing under ICH Q1B where light matters. For cosmetics and supplements, we adapt the same logic to the product's market and claims.

What you receive

01

Root-cause assessment

A written analysis of why a current formulation fails. It links observed symptoms to likely mechanisms, such as oxidation, pH drift, supersaturation or polymer degradation, and lists the experiments that would confirm each.

02

Formulation strategy

Ranked options for excipients, solvent systems, delivery vehicles and processing. Each option comes with its rationale, known risks, regulatory acceptability in your markets and the data needed before you commit.

03

Prototype screening design

A compact experimental plan, often a designed experiment, that defines compositions, process settings, responses and decision rules. It is written so your laboratory or contract manufacturer can run it without guesswork.

04

Stability study protocol

Storage conditions, time points, stress tests, packaging and test attributes for your product type. It includes forced degradation to support a stability-indicating method and clear criteria for shelf-life claims.

05

Characterization plan

The physical, chemical and performance tests that define quality, such as droplet or particle size, rheology, pH, assay, impurities, release and microscopy. Each method is matched to a critical attribute.

06

Scale-up risk review

An assessment of which steps may behave differently at larger scale, such as mixing, heating, homogenization or filling. It names the parameters to fix before technology transfer to a manufacturer.

How a formulation engagement runs

Define the target

We agree what the product must do: dose, route, texture, shelf life, claims and markets. Where a target product profile exists, we work from it. Otherwise we draft the critical quality attributes with you first.

Diagnose and design

We review your data, raw material specifications and the literature. We then propose formulation options and a focused experimental plan, with clear decision rules for what counts as success at each stage.

Review and iterate

We interpret results with your team, refine the composition and update the stability and characterization plans. Each round ends with a written decision and the next experiments, so progress stays traceable.

How this work typically looks

A

Cosmetic brand

Curcumin serum loses color and potency in storage

Situation
A serum built around curcumin fades from bright yellow within weeks, and assay values fall. The base is mildly alkaline and packed in a clear bottle. The brand wants a stable product with a credible claim, without a heavy or greasy texture.
How we advise
We trace the losses to known curcumin behavior: very low water solubility, rapid degradation at neutral to alkaline pH, and photodegradation. We recommend a mildly acidic base, light-protective packaging and antioxidant support. We compare cyclodextrin complexes, liposomes and nanoemulsions for solubility and protection. A stability-indicating HPLC method then tracks curcumin and its degradation products.
What you receive
A reformulation plan with ranked delivery options, a packaging recommendation, an HPLC stability protocol, and acceptance criteria for color and assay over shelf life.
B

Specialty pharmaceutical company

Topical drug crystallizes in the tube

Situation
A topical formulation looks clear at release, but crystals appear after some months in storage. The active was dissolved close to its saturation limit in a mixed solvent system. Crystals reduce the dose available to the skin and raise quality questions.
How we advise
We map the solubility of the active across solvent ratios and temperatures to find where supersaturation arises. We check whether evaporation, temperature cycling or a polymorphic change triggers nucleation. Options include rebalancing cosolvents, lowering the drug load or adding a polymeric crystallization inhibitor. Polarized light microscopy, XRPD and DSC confirm the solid form.
What you receive
A root-cause report, a revised solvent system proposal, a temperature-cycling and stability protocol, and a test panel that detects crystallization early.
C

Drug-delivery start-up

Designing an injectable hydrogel for sustained release

Situation
A team wants an injectable depot that releases a drug over several weeks. Early prototypes either gel too fast in the syringe or release most of the drug in the first day. They need a rational polymer choice before animal studies.
How we advise
We compare in-situ forming options, such as thermoresponsive polymers, ionically crosslinked polysaccharides and shear-thinning networks, against the drug's size and solubility. We define rheology and injection-force tests for injectability. We design in vitro release studies and fit the data to models that help distinguish diffusion-controlled from degradation-controlled release. Sterilization compatibility is checked early.
What you receive
A polymer and gelation strategy, an injectability and rheology test plan, an in vitro release protocol with a modeling approach, and a list of open risks.

Illustrative scenarios. Each is a composite of common client situations, not a specific engagement.

Frequently asked questions

What do your formulation services cover?

We cover the technical side of formulation: diagnosing failures, choosing excipients and delivery systems, designing experiments, and defining characterization and stability testing. Products include topical and injectable drugs, cosmetics, nutraceuticals and hydrogel-based biomaterials. We design the work and interpret the results. Your team, contract manufacturer or chosen laboratory makes the batches and runs the tests.

What information do you need to start?

Send the active's identity and known properties, the current composition and process, the target concentration, intended markets, and any stability or analytical data. Photos of failed batches are often useful. Include raw material specifications or supplier certificates if you have them. Gaps are fine; we list what to measure first.

How long does formulation development take?

A feasibility assessment is a short desk-based step; its length depends mainly on how much data you already hold. Full development depends on the number of iteration rounds and on stability time points, which effort alone cannot shorten. Accelerated conditions give early signals, but shelf-life claims rest on real-time data. We set out a realistic timeline in the written quote.

Do you work on cosmetics and supplements as well as drugs?

Yes. The chemistry is often the same, but the expectations differ. A drug product needs ICH-aligned stability data and validated analytical methods. A cosmetic needs safety substantiation and evidence for its claims under the rules of each market. We design the work for the category your product actually falls into.

What happens after the first assessment?

You receive a written assessment with ranked options and a test plan. Many clients then run the first screening round and bring results back for interpretation. Others move to a characterization plan or a scale-up risk review. Each step is scoped separately, so you commit only to the next piece of work.

What happens after I contact you?

A scientist follows up by email about your product, the problem you’re seeing, your data, and target markets. We confirm which photos or batch records will help and send a written quote for your approval.

Have a formulation that is not behaving?

Describe the product, the problem you’re seeing, and what you’ve tried. We’ll follow up by email and send a written quote for reviewing the likely causes and recommending what to test first.